Project Grant R01AG085557
Award Date
9/26/24
Completion Date
6/30/29
Dollars Obligated
$2M
Federal Agency
National Institute on Aging
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
The National Institute on Aging (NIA) awarded a $828,534 Cooperative Agreement under the Aging Research federal grant program (CFDA 93.866) to the University of Massachusetts Medical School (UMass Medical) to conduct a molecular dissection of the neuronal-adaptive immune-genomic axis. The goal is to identify novel integrative factors contributing to Alzheimer's disease (AD) pathogenesis or to the protection of brain neurons in the aging process. The project will apply large-scale, innovative,...
This Project Grant award from the National Institute on Aging's (NIA) Aging Research program (CFDA 93.866) provides $3,038,050 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to study the molecular mechanisms of Alzheimer's disease. The funded research aims to discover a novel oxidative stress pathway that targets microglia, the immune cells in the brain, leading to their dysfunction and detrimental consequences in Alzheimer's disease. The goal is to develop...
This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
The National Institute on Aging (NIA) awarded a $442,357 Project Grant under the Aging Research program (CFDA 93.866) to the Research Foundation of the City University of New York (RFCUNY) on December 15, 2024. The grant aims to elucidate the molecular mechanisms that give rise to functionally neurodegenerative microglia, the brain's primary innate immune cells, which have been implicated as major determinants of Alzheimer's disease (AD) risk. The research will leverage novel mouse models and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support Emory University's research into the genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease and related dementias. The $528,876 award, effective June 1, 2025, will fund the development of new analytic tools to integrate genomic data across multiple tissues and improve the identification of genetic risk factors and underlying molecular mechanisms for...
This $614,424 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to better understand the role of microglia, the brain's immune cells, in the development of Alzheimer's disease (AD). The University of Washington (UW) will leverage novel explainable AI techniques and human induced pluripotent stem cell (iPSC) models to uncover subtle microglial changes that occur early in AD progression. Specifically, UW will expose microglia-neuron iPSC cultures to...
This federal Project Grant award of $2,833,089 was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes. The award will support research to investigate the roles of the TREM2 and TYROBP genes and their impact on network hyperexcitability, which may contribute to cognitive decline in Alzheimer's disease and related dementias. Key objectives include determining whether TYROBP hypofunction exacerbates network...
This federal Project Grant award from the National Institute on Aging (NIA), under CFDA Program 93.866 Aging Research, provides $613,571 to the University of Chicago to develop an in vivo gene therapy approach for treating Alzheimer's disease. The project aims to engineer chimeric antigen receptor (CAR)-expressing microglia that can recognize and clear amyloid-beta plaques, a key pathological hallmark of Alzheimer's. The researchers will package mRNA encoding anti-amyloid-beta CAR constructs and...
This Project Grant award, totaling $679,424, was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to Colorado State University. The project aims to test the efficacy of a novel therapeutic targeting neuroinflammation for protecting against brain aging and Alzheimer's disease-related pathology. Specifically, the research will evaluate the role of the neuroinflammation mediators NF-kB and NLRP3 using a novel class of small molecule...
This Project Grant award of $766,133 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to understand the mechanisms leading to amyloid-related imaging abnormalities (ARIA) that can occur with anti-amyloid immunotherapy for Alzheimer's disease. The research aims to: Determine the elimination pathway and clearance mechanism for chimeric anti-amyloid antibodies (ChAbs) in Alzheimer's disease mouse models. Examine how ARIA events develop in Alzheimer's disease...